Neurological Disorder Drugs Market Insights & Growth Forecast During 2018-2026

Posted by Rajkumar on March 11th, 2019

Neurological disorder is associated with dysfunction in any part of the brain or nervous system, resulting in physical and/or psychological symptoms. Various neurological disorders are congenital, which emerge during the early years of embryo developmental and may be diagnosed at birth. Whereas, acquired neurological disorders develop after the birth due to traumatic brain injuries, immune disorders, postnatal injections, spinal cord injuries, neoplasm, and exposure to environmental chemicals or toxins, among others.

 

Many bacterial (Mycobacterial tuberculosis, Neisseria meningitides), viral (Human Immunodeficiency Virus (HIV), Enteroviruses, West Nile Virus, Zika), fungal (Cryptococcus, Aspergillus), and parasitic (malaria, Chagas) infections can also affect the nervous system, resulting in neurological disorders.

 

Ask For In-Depth Sample Copy of Research @ https://www.coherentmarketinsights.com/insight/request-sample/2363

 

Neurological Disorder Drugs Market: Drivers

 

Rising awareness associated with early disease diagnosis through awareness campaigns by government regulatory bodies and private organizations, and market entry of efficient drugs in the near future, owing to the presence of strong drug pipeline is expected to drive growth of the neurological disorder drugs market.

 

For instance, according to a report published by the Pharmaceutical Research and Manufacturers of America (PhRMA) in April 2018, there are currently 537 medicines in development by biopharmaceutical companies in the U.S for various neurological disorders. This mainly includes 95 medicines for brain tumors, 46 for chronic pain, and 92 for Alzheimer’s disease. The other 30 are being developed for a range of conditions including multiple sclerosis, migraines, amyotrophic lateral sclerosis, and Parkinson’s disease.

 

Neurological Disorder Drugs Market: Regional Analysis

 

North America is expected to hold a dominant position in the global neurological disorder drugs market and account for the largest market share over the forecast period, owing to high presence of key players in the region and approval and launch of novel products by them in the region.

 

For instance, in May 2018, Amgen received the U.S. FDA approval for Aimovig (erenumab-aooe), for the preventive treatment of migraine in adults. Aimovig is a novel therapeutic approach and the only FDA-approved treatment specifically developed to prevent migraine by blocking the calcitonin gene-related peptide receptor (CGRP-R), which plays a critical role in migraine.

 

Neurological Disorder Drugs Market: Key Players

 

Key players operating in the global neurological disorder drugs market include Amgen Inc., UCB S.A., Neurocrine Biosciences, Inc., Pfizer Inc., Biogen Inc., Teva Pharmaceutical Industries Ltd., AcelRx Pharmaceuticals, Inc., Eli Lilly and Company, Ionis Pharmaceuticals, Inc., Adamas Pharmaceuticals, Inc., BioMarin Pharmaceutical Inc., Otsuka America Pharmaceutical, Inc., AstraZeneca plc, and Novartis International AG.

 

Neurological Disorder Drugs Market: Taxonomy

 

The global neurological disorder drugs market is segmented on the basis of drug type, disease type, distribution channel, and region.

 

By Drug Type:

 

  • Antipsychotic

  • Antiepileptic

  • Anticholinergic

  • Analgesics

  • Hypnotic & Sedative

  • Anticoagulants

  • Antihypertensive

 

By Disease Type:

 

  • Epilepsy

  • Parkinson’s disease

  • Alzheimer’s disease

  • Cerebrovascular disease

  • Multiple Sclerosis

  • Others

 

By Distribution Channel:

 

  • Hospitals Pharmacies

  • Retail Pharmacies

  • Online pharmacies

 

By Region:

 

  • North America

  • Latin America

  • Europe

  • Asia Pacific

  • Middle East

  • Africa

 

For More Information, Browse Full Report Here: https://www.coherentmarketinsights.com/ongoing-insight/neurological-disorder-drugs-market-2363

 

Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential. For more information or to access this database, kindly click on the below link or contact at sales@coherentmarketinsights.com

 

https://www.coherentmarketinsights.com/phase-xs/

 

About Coherent Market Insights:

 

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

 

Contact Us:

 

Mr. Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Like it? Share it!


Rajkumar

About the Author

Rajkumar
Joined: February 13th, 2019
Articles Posted: 590

More by this author